Alcohol Addiction - Pipeline Review, H2 2016

Date: July 20, 2016
Pages: 138
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: AFD1F7660B2EN
Leaflet:

Download PDF Leaflet

Alcohol Addiction - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Alcohol Addiction - Pipeline Review, H2 2016’, provides an overview of the Alcohol Addiction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Alcohol Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alcohol Addiction and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Alcohol Addiction
  • The report reviews pipeline therapeutics for Alcohol Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Alcohol Addiction therapeutics and enlists all their major and minor projects
  • The report assesses Alcohol Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Alcohol Addiction
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Alcohol Addiction
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Alcohol Addiction pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Alcohol Addiction Overview
Therapeutics Development
Pipeline Products for Alcohol Addiction - Overview
Pipeline Products for Alcohol Addiction - Comparative Analysis
Alcohol Addiction - Therapeutics under Development by Companies
Alcohol Addiction - Therapeutics under Investigation by Universities/Institutes
Alcohol Addiction - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Alcohol Addiction - Products under Development by Companies
Alcohol Addiction - Products under Investigation by Universities/Institutes
Alcohol Addiction - Companies Involved in Therapeutics Development
AbbVie Inc.
Addex Therapeutics Ltd
Adial Pharmaceuticals, LLC
Astraea Therapeutics, LLC
AstraZeneca Plc
Bionex Pharmaceuticals LLC
Bioprojet SCR
Cerecor Inc.
Curemark, LLC
Eli Lilly and Company
Ethypharm S.A.
Euthymics Bioscience, Inc.
H. Lundbeck A/S
Heptares Therapeutics Limited
Indivior Plc
Johnson & Johnson
Kinnov Therapeutics SAS
Kyorin Pharmaceutical Co., Ltd.
Lohocla Research Corporation
Omeros Corporation
Pfizer Inc.
SK Biopharmaceuticals Co., Ltd.
Tonix Pharmaceuticals Holding Corp.
VM Discovery, Inc.
XenoPort, Inc.
Zynerba Pharmaceuticals, Inc.
Alcohol Addiction - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(cyproheptadine hydrochloride + prazosin hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(disulfiram + selegiline) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
A-705253 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABT-436 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADX-71441 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amitifadine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
arbaclofen placarbil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
baclofen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
carisbamate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CERC-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CM-1212 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gabapentin enacarbil ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GET-73 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibudilast - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JDTic - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-5234801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nalmefene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naltrexone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naltrexone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
odelepran hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMS-527 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ondansetron hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-05190457 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pitolisant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
saracatinib difumarate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKL-10406 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Alcohol Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Oxytocin Receptor for Alcohol Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize NOP for Pain and Alcohol Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize GABAA1 for Alcohol Addiction and Anxiety - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VMD-2202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Alcohol Addiction - Dormant Projects
Alcohol Addiction - Discontinued Products
Alcohol Addiction - Product Development Milestones
Featured News & Press Releases
Jun 29, 2016: MediciNova Announces Results from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana
May 25, 2016: MediciNova Announces Additional Results from the Completed Trial of MN-166 (ibudilast) in Alcohol Dependence to be Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana
Dec 11, 2015: Publication Reports Human Brain Penetration and Target Engagement of Cerecor’s Oral Kappa Opioid Receptor Antagonist, CERC-501
Dec 09, 2015: MediciNova Announces Positive Findings From a Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder (AUD) Reported at the American College of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting
Oct 13, 2015: Addex’ ADX71441 Demonstrates Robust Efficacy in Multiple Preclinical Models of Alcohol Use Disorder
Oct 01, 2015: XenoPort Announces Plan to Focus on its Growing HORIZANT Business and Names Vincent J. Angotti Chief Executive Officer and Director
Jun 30, 2015: MediciNova Announces the Completion of Enrollment in Clinical Trial of MN-166 in Alcohol Dependence
Jun 25, 2015: XenoPort Announces Initiation by NIAAA of Clinical Trial of HORIZANT in Patients with Alcohol Use Disorder
Jun 24, 2015: MediciNova Announces Presentation of Interim Data from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence at the 38th Annual RSA (Research Society on Alcoholism) Scientific Meeting
Jan 11, 2015: XenoPort Provides Highlights of HORIZANT Prescription Trends and Update on Development for Alcohol Use Disorder
Jan 07, 2015: Addex and NIAAA Enter Collaboration to Evaluate ADX71441 in Alcohol Use Disorder
Nov 26, 2014: Biotie: UK's Nice Issues Positive Final Guidance For Selincro
Nov 26, 2014: Drug recommended to help cut drink dependence
Sep 09, 2014: XenoPort and the NIAAA Announce Clinical Trial Agreement to Study HORIZANT as a Potential Treatment for Alcohol Use Disorder
Jul 10, 2014: NICE recommends nalmefene treatment for alcohol dependence
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Alcohol Addiction, H2 2016
Number of Products under Development for Alcohol Addiction - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Alcohol Addiction - Pipeline by AbbVie Inc., H2 2016
Alcohol Addiction - Pipeline by Addex Therapeutics Ltd, H2 2016
Alcohol Addiction - Pipeline by Adial Pharmaceuticals, LLC, H2 2016
Alcohol Addiction - Pipeline by Astraea Therapeutics, LLC, H2 2016
Alcohol Addiction - Pipeline by AstraZeneca Plc, H2 2016
Alcohol Addiction - Pipeline by Bionex Pharmaceuticals LLC, H2 2016
Alcohol Addiction - Pipeline by Bioprojet SCR, H2 2016
Alcohol Addiction - Pipeline by Cerecor Inc., H2 2016
Alcohol Addiction - Pipeline by Curemark, LLC, H2 2016
Alcohol Addiction - Pipeline by Eli Lilly and Company, H2 2016
Alcohol Addiction - Pipeline by Ethypharm S.A., H2 2016
Alcohol Addiction - Pipeline by Euthymics Bioscience, Inc., H2 2016
Alcohol Addiction - Pipeline by H. Lundbeck A/S, H2 2016
Alcohol Addiction - Pipeline by Heptares Therapeutics Limited, H2 2016
Alcohol Addiction - Pipeline by Indivior Plc, H2 2016
Alcohol Addiction - Pipeline by Johnson & Johnson, H2 2016
Alcohol Addiction - Pipeline by Kinnov Therapeutics SAS, H2 2016
Alcohol Addiction - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016
Alcohol Addiction - Pipeline by Lohocla Research Corporation, H2 2016
Alcohol Addiction - Pipeline by Omeros Corporation, H2 2016
Alcohol Addiction - Pipeline by Pfizer Inc., H2 2016
Alcohol Addiction - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
Alcohol Addiction - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2016
Alcohol Addiction - Pipeline by VM Discovery, Inc., H2 2016
Alcohol Addiction - Pipeline by XenoPort, Inc., H2 2016
Alcohol Addiction - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Alcohol Addiction - Dormant Projects, H2 2016
Alcohol Addiction - Dormant Projects (Contd..1), H2 2016
Alcohol Addiction - Dormant Projects (Contd..2), H2 2016
Alcohol Addiction - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Alcohol Addiction, H2 2016
Number of Products under Development for Alcohol Addiction - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

AbbVie Inc.
Addex Therapeutics Ltd
Adial Pharmaceuticals, LLC
Astraea Therapeutics, LLC
AstraZeneca Plc
Bionex Pharmaceuticals LLC
Bioprojet SCR
Cerecor Inc.
Curemark, LLC
Eli Lilly and Company
Ethypharm S.A.
Euthymics Bioscience, Inc.
H. Lundbeck A/S
Heptares Therapeutics Limited
Indivior Plc
Johnson & Johnson
Kinnov Therapeutics SAS
Kyorin Pharmaceutical Co., Ltd.
Lohocla Research Corporation
Omeros Corporation
Pfizer Inc.
SK Biopharmaceuticals Co., Ltd.
Tonix Pharmaceuticals Holding Corp.
VM Discovery, Inc.
XenoPort, Inc.
Zynerba Pharmaceuticals, Inc.
Skip to top


Addiction - Pipeline Review, H1 2015 US$ 1,600.00 Mar, 2015 · 287 pages
Smoking Addiction - Pipeline Review, H1 2016 US$ 2,000.00 Jun, 2016 · 107 pages
Alcoholic Hepatitis - Pipeline Review, H2 2016 US$ 2,000.00 Sep, 2016 · 67 pages
Alcohol Addiction - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages
Drug Addiction - Pipeline Review, H2 2015 US$ 1,600.00 Oct, 2015 · 95 pages

Ask Your Question

Alcohol Addiction - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: